Zorifertinib Achieves 67% Intracranial Response in NSCLC Brain Metastases: EVEREST Phase 3 Results
Quick Facts
Why Do Lung Cancer Patients Need a Brain-Penetrating EGFR Drug?
Brain metastases represent one of the most devastating complications of EGFR-mutant non-small cell lung cancer, affecting 25-40% of patients during their disease course. While existing EGFR tyrosine kinase inhibitors such as osimertinib and first-generation agents (gefitinib, erlotinib) show some intracranial activity, their cerebrospinal fluid (CSF) penetration remains limited, meaning brain concentrations may fall below the threshold needed to control resistant tumor clones effectively.
Zorifertinib (AZD3759) was rationally designed using computational modeling to maximize blood-brain barrier penetration while maintaining potent EGFR inhibition against sensitizing mutations (exon 19 deletion, L858R). Preclinical studies published in Science Translational Medicine in 2016 demonstrated that zorifertinib achieves near-unity brain-to-plasma unbound concentration ratios (Kpuu approaching 1.0), representing dramatically higher brain exposure than conventional EGFR inhibitors. The Phase 3 EVEREST trial (NCT03653546) enrolled 439 patients with EGFR-mutant NSCLC and CNS metastases across multiple centers, with results published in Med (Cell Press) in January 2025.
What Did the EVEREST Trial Show About Zorifertinib's Effectiveness?
The EVEREST trial randomized 439 patients 1:1 to zorifertinib or investigator's choice of first-generation EGFR TKI (gefitinib or erlotinib) as first-line treatment. The trial showed zorifertinib's superiority in both intracranial and systemic disease control. Intracranial objective response rate by blinded independent central review was approximately 74% for zorifertinib versus approximately 63% for the control arm. Systemic objective response rate was 68.6% versus 58.4% (p = 0.027). Median systemic progression-free survival was 9.6 months with zorifertinib versus 6.9 months with first-generation EGFR TKIs (HR 0.719, p = 0.0024), with intracranial PFS also significantly favoring zorifertinib (HR 0.467 by BICR).
Overall survival data, though immature at the time of primary analysis, showed a trend favoring zorifertinib (estimated median 37.3 vs 31.8 months, HR 0.833). The safety profile was consistent with the EGFR inhibitor class, with common adverse events including rash, diarrhea, and elevated aminotransferases. Based on these results, the China NMPA approved zorifertinib (brand name Zorifer) in November 2024 for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation and CNS metastases — making it the world's first EGFR-TKI specifically approved for lung cancer patients with brain metastases. As of early 2026, zorifertinib has not received FDA approval in the United States.
Frequently Asked Questions
The EVEREST trial compared zorifertinib to first-generation EGFR TKIs (gefitinib/erlotinib), not directly to osimertinib, which is the current global standard of care. Head-to-head trials comparing zorifertinib to osimertinib would be needed to determine relative efficacy. Zorifertinib's current approval in China is specifically for EGFR-mutant NSCLC patients with CNS metastases.
Zorifertinib is approved for EGFR-mutant NSCLC with exon 19 deletions and exon 21 L858R point mutations — the two most common sensitizing EGFR mutations. Its activity against the T790M resistance mutation and uncommon EGFR mutations is an area of ongoing research.
In the EVEREST trial, zorifertinib's high brain penetration did not appear to cause unique central nervous system toxicities. The adverse event profile was generally consistent with other EGFR inhibitors, including rash, diarrhea, and liver enzyme elevations. The safety data suggest that achieving high brain drug concentrations does not inherently increase the risk of neurological side effects.
References
- Zhou Q, Wu YL, Wang J, Ahn MJ, et al. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. Med. 2025;6(1):100513.
- Zeng Q, Wang J, Cheng Z, et al. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J Med Chem. 2015;58(20):8200-8215.
- Yang Z, Guo Q, Wang Y, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases: A Phase I pharmacokinetic and preliminary efficacy study. Sci Transl Med. 2016;8(368):368ra172.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025.